Biogen Collaborates with Capsigen to Discover Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

 Biogen Collaborates with Capsigen to Discover Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

Shots:

  • Capsigen to receive $15M up front and is eligible to receive up to ~$42M as research milestones and ~$1.25B as additional payments upon the achievement of development and sales milestones along with royalties on net sales of products resulting from the collaboration
  • Biogen to get an exclusive license under Capsigen’s technology for CNS and neuromuscular disease targets
  • The collaboration leverages Capsigen’s TRADE platform and associated technologies to identify novel AAV capsids with Biogen’s discovery, development, manufacturing and commercialization capabilities to facilitate the delivery of gene therapies for needy patients

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Biogen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post